Suppression of human IL-1β, IL-2, IFN-γ, and TNF-α production by cigarette smoke extracts

Abstract

Background: Although cigarette smoking is known to have detrimental effects on the immune system, the nature of the immunosuppressive agent or agents is poorly understood. Objective: The purpose of the current study was to evaluate the effects of cigarette smoke extracts from high-tar (unfiltered Camel), medium-tar (Marlboro), and low-tar (Carlton) cigarettes on the in vitro production of IL-1β, IL-2, IFN-γ, and TNF-α. Methods: The concentrations of hydroquinone and catechol in cigarette smoke extracts were determined by using HPLC. Human PBMCs were treated with cigarette smoke extracts, hydroquinone, or catechol, and stimulated with anti-CD3 and phorbol-12-myristate-13-acetate. Cytokine levels in the supernatants were quantified by ELISA. Results: Pretreatment of PBMCs with cigarette smoke extracts derived from a single high- or low-tar cigarette suppressed the production of IL-1β, IL-2, IFN-γ, and TNF-α by greater than 90% without significant loss of cell viability. Nicotine, at a concentration comparable with that found in the highest-tar cigarettes (200 μg/mL), suppressed the production of IL-2, IFN-γ, and TNF-α by only 21% to 38%. Catechol (50 μmol/L) inhibited production of IL-2 and IL-1β by 62% to 73% but had little effect on TNF-α or IFN-γ production. In contrast, hydroquinone inhibited the production of all 4 cytokines with IC50 values ranging from 3 μmol/L(IL-1β) to 29 μmol/L (IFN-γ). However, HPLC determination of the hydroquinone concentrations in cigarette smoke extracts from single Camel (33 ± 4 μmol/L), Marlboro (13 ± 2 μmol/L), and Carlton (<1 μmol/L) cigarettes clearly demonstrated that the potent inhibitory effects of the low-tar cigarettes could not be accounted for by either hydroquinone or catechol. Conclusion: These studies indicate that cigarette smoke contains potent inhibitors of cytokine production, at least one of which is present even in low-tar cigarettes. (J Allergy Clin Immunol 2000;106:280-7.)